Skip to Content
Merck
All Photos(1)

Key Documents

I2516

Sigma-Aldrich

Isocitric Dehydrogenase (NADP) from porcine heart

lyophilized powder, 20-60 units/mg protein (biuret)

Synonym(s):

threo-Ds-Isocitrate: NADP+ oxidoreductase, ICDH, IDH

Sign Into View Organizational & Contract Pricing


About This Item

CAS Number:
Enzyme Commission number:
EC Number:
MDL number:
UNSPSC Code:
12352204
Pricing and availability is not currently available.

form

lyophilized powder

specific activity

20-60 units/mg protein (biuret)

composition

Protein, ~20%

storage temp.

−20°C

Looking for similar products? Visit Product Comparison Guide

Quality

Highly purified
Essentially free of aconitase activity.

Unit Definition

One unit will convert 1.0 μmole of isocitrate to α-ketoglutarate per min at pH 7.4 at 37°C.

Physical form

Lyophilized powder containing sodium citrate and manganous sulfate

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Precautionary Statements

Hazard Classifications

Resp. Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Omar Abdel-Wahab et al.
Hematology. American Society of Hematology. Education Program, 2012, 56-64 (2012-12-13)
The myelodysplastic syndromes (MDS) are a clinically and cytogenetically heterogeneous group of clonal diseases characterized by ineffective hematopoiesis, peripheral blood cytopenias, and an increased risk of progression to acute myeloid leukemia. The precise molecular mechanisms behind the development of MDS
Maria Paola Martelli et al.
Blood reviews, 27(1), 13-22 (2012-12-25)
Acute myeloid leukemia (AML) is a molecularly heterogeneous disease. Based on cytogenetics and FISH, AML patients are stratified into three major risk categories: favourable, intermediate and unfavourable. However, prognostic stratification and treatment decision for the intermediate risk category, that mostly
O Zalatimo et al.
Advances in experimental medicine and biology, 779, 267-289 (2013-01-05)
Primary brain tumors constitute a substantial public health problem with 66,290 cases diagnosed in the US in 2012, and 13,700 deaths recorded. With discovery of genetic factors associated with specific brain tumor subtypes, the goal of therapy is changing from
Lynn J Poole Perry et al.
American journal of ophthalmology, 155(3), 593-608 (2012-12-12)
To evaluate the cellular nature of and diagnostic terminology used in connection with acquired retinal "vasoproliferative tumors." Retrospective clinicopathologic study. Clinical records and microscopic slides of 4 enucleated globes were reviewed. Special stains and immunohistochemical probes for CD31, CD34, p53
Jay P Patel et al.
Hematology. American Society of Hematology. Education Program, 2012, 28-34 (2012-12-13)
Acute myeloid leukemia (AML) is the most common acute leukemia diagnosed in adults, and the majority of patients with AML die from relapsed disease. Although many studies over the past 4 decades have identified disease alleles in AML, recent genome-wide

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service